Approach to the management of portal hypertensive gastropathy and gastric antral vascular ectasia
Bezawit D. Tekola, Stephen Caldwell – 9 November 2012 – Watch a video presentation of this article
Donation after cardiac death liver transplantation: Another fly in the ointment
Neehar D. Parikh, Anton I. Skaro – 2 November 2012
HCC Is promoted by bacterial translocation and TLR‐4 signaling: A new paradigm for chemoprevention and management
Sara Toffanin, Helena Cornella, Andrew Harrington, Josep M. Llovet – 31 October 2012
Reply:
Naoki Tanaka, Frank J. Gonzalez – 31 October 2012
Cholesterol and nonalcoholic fatty liver disease: Renewed focus on an old villain
Thomas A. Kerr, Nicholas O. Davidson – 31 October 2012
PPARα activation in portal hypertension
Hongqun Liu, Samuel S. Lee – 31 October 2012
Natural killer cells in liver disease
Zhigang Tian, Yongyan Chen, Bin Gao – 30 October 2012 – Natural killer (NK) cells are enriched in lymphocytes within the liver and have unique phenotypic features and functional properties, including tumor necrosis factor–related apoptosis‐inducing ligand–‐dependent cytotoxicity and specific cytokine profiles.
Natural killer cells in liver disease
Zhigang Tian, Yongyan Chen, Bin Gao – 30 October 2012 – Natural killer (NK) cells are enriched in lymphocytes within the liver and have unique phenotypic features and functional properties, including tumor necrosis factor–related apoptosis‐inducing ligand–‐dependent cytotoxicity and specific cytokine profiles.
Donor‐derived long‐lived intragraft leukocytes are likely generated by hematopoietic stem/progenitor cells in liver
Xiao Qi Wang, Cindy K.Y. Cheung, Chung Mau Lo – 30 October 2012
Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon‐induced hepatitis B e antigen seroconversion
Hung‐Chih Yang, Chi‐Ling Chen, Yueh‐Chi Shen, Cheng‐Yuan Peng, Chun‐Jen Liu, Tai‐Chung Tseng, Tung‐Hung Su, Wan‐Long Chuang, Ming‐Lung Yu, Chia‐Yen Dai, Chen‐Hua Liu, Pei‐Jer Chen, Ding‐Shinn Chen, Jia‐Horng Kao – 30 October 2012 – Precore (PC) (G1896A) and basal core promoter (BCP) (A1762T/G1764A) mutations of the hepatitis B virus (HBV) genome often emerge in chronic hepatitis B (CHB) patients. Their roles in hepatitis B e antigen (HBeAg) seroconversion induced by interferon (IFN) therapy remain controversial, partly because quantitative analysis for these mutants is lacking.